Lupin in South Africa

Lupin Expands Presence in South Africa with Acquisition of Nine Health Brands

Cape Town, South Africa – October 4, 2024

Lupin Limited, a global pharmaceutical leader headquartered in Mumbai, India, has announced a significant expansion in the South African market. Through its subsidiary, Pharma Dynamics, Lupin has acquired nine health brands from the Medical Nutritional Institute SA (MNI), in partnership with South African investment firm ImpiloVest. The acquired brands include AntaGolin, RyChol, NeuroVance, SkinVance, FlamLeve, Rheumalin, SleepVance, ImmunoVance, and OviVance. These products address a range of health concerns such as metabolic syndrome, insulin resistance, cognitive function, skin health, inflammation, joint care, sleep quality, immune support, and women’s hormonal well-being. (lupin.com)

Thierry Volle, President EMEA at Lupin, emphasized the strategic importance of this acquisition, stating, “This acquisition is a major step for Lupin to expand our footprint in the Complementary and Alternative Medicines sector. MNI’s innovative plant-based products align perfectly with our goal to provide holistic and sustainable healthcare solutions to our patients in South Africa.” (lupin.com)

Erik Roos, CEO of Pharma Dynamics, highlighted the growing demand for proactive healthcare solutions, noting, “This acquisition broadens our product range by concentrating on metabolic diseases such as cardiovascular disease, diabetes, and neuroscience, thereby enhancing patient health and well-being.” (lupin.com)

Mariaan du Plessis, CEO of MNI, expressed enthusiasm about the partnership, stating, “We are proud to partner with a company that shares our dedication to holistic and preventive healthcare. MNI’s unique plant-based formulations, developed in 2002 by a team of healthcare professionals, have been extensively tested to ensure their efficacy.” (lupin.com)

READ Sona Comstar in South Africa

This acquisition marks a significant milestone in Lupin’s strategy to enhance its presence in the complementary and alternative medicines sector, aligning with the company’s commitment to providing comprehensive healthcare solutions in South Africa.

Lupin Limited is a global pharmaceutical company specializing in branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. With a strong presence in over 100 markets, Lupin is dedicated to improving patient health outcomes through its diverse product portfolio. (lupin.com)

For more information, please visit Lupin’s official website at www.lupin.com.

This article is based on information available as of October 4, 2024.